Induction Immunosuppressive Therapies in Renal Transplantation

Steven Gabardi, Pharm.D., BCPS; Spencer T. Martin, Pharm.D., BCPS; Keri L. Roberts, Pharm.D.; Monica Grafals, M.D.


Am J Health Syst Pharm. 2011;68(3):211-218. 

In This Article

Data Sources

Articles for this review were identified through searches of MEDLINE (January 1965–April 2010) using the search terms induction therapy, renal transplantation, antithymocyte globulin rabbit, antithymocyte globulin horse, muromonab-CD3, basiliximab, daclizumab, and alemtuzumab. Bibliographies of articles retrieved were also reviewed for relevant trials. Clinical trials were included if they involved renal transplant recipients, included a control group, and were deemed to be of moderate-to-high quality. All English-language in vitro and in vivo studies evaluating induction therapy agents were also reviewed and considered for inclusion.


Comments on Medscape are moderated and should be professional in tone and on topic. You must declare any conflicts of interest related to your comments and responses. Please see our Commenting Guide for further information. We reserve the right to remove posts at our sole discretion.